Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002400 · ClinicalTrials.gov registry record · NA
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
A NA study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT00002400: Completed NA study, sponsored by Pharmacia and Upjohn.
NCT00002400 is a NA study that has completed, run by Pharmacia and Upjohn. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002400, a NA study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Phase | NA |
What the finished NCT00002400 record still lists
NCT00002400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Zidovudine is the first listed.
NCT00002400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002400 about?
NCT00002400 is a clinical study titled "A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients". The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with...
What is the current status of trial NCT00002400?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants.
What interventions are being tested in trial NCT00002400?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002400?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002400's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors